GlassScriptPhysician profile
Bashir Adam Koko
NPI 1003538273
$1,531.14
in general payments reported to CMS, 2019-2025
12 companies · $986 in 2025
The $986 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.22 · 2023: $129 · 2024: $363 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $370.25 | 2024-2025 | |
| Solventum Corporation | $361.49 | 2024-2025 | Prevena, V.A.C. Granufoam, V.A.C. Veraflo Cleanse Choice |
| Kerecis Limited | $256.02 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Cvrx, INC. | $150.85 | 2024 | Barostim Neo System |
| Atricure, INC. | $117.79 | 2023-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Acera Surgical, INC. | $109.54 | 2025 | Restrata Wound Matrix |
| Medtronic, INC. | $53.22 | 2022 | |
| Silk Road Medical, INC. | $39.64 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Lilly USA, LLC | $19.94 | 2025 | Zepbound |
| Kci USA, INC. | $19.14 | 2023 | Prevena, Abthera Advance, V.A.C. Veraflo Cleanse Choice |
| W. L. Gore & Associates, INC. | $17.00 | 2025 | Propaten Bioactive Surface |
| Takeda Pharmaceuticals U.S.A., INC. | $16.26 | 2025 | Livtencity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Koko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.